National Health Investors (NYSE:NHI) Trading Down 5.2% - Here's What Happened

Key Points

• National Health Investors shares fell 5.2% to about $70.28, despite second-quarter revenue of $121.32 million and EPS of $1.19 exceeding analyst estimates.
• Investors appeared more concerned about FFO of $1.19 per share missing consensus and fiscal 2026 EPS guidance of $4.74–$4.79 trailing the $4.87 estimate.
• NHI declared a quarterly dividend of $0.92 per share, or $3.68 annually, representing an approximately 5.2% yield; analysts maintain a “Moderate Buy” consensus with an $83.86 price target.

Shares of National Health Investors, Inc. (NYSE:NHI - Get Free Report) fell 5.2% on Tuesday . The stock traded as low as $69.91 and last traded at $70.2830. 35,506 shares changed hands during trading, a decline of 92% from the average daily volume of 433,820 shares. The stock had previously closed at $74.15.

Key National Health Investors News

Here are the key news stories impacting National Health Investors this week:

• Positive Sentiment: NHI reported second-quarter revenue of $121.32 million, up 1.6% year over year and well above the approximately $72.12 million analyst estimate. Reported EPS of $1.19 also exceeded the $0.84 consensus estimate. NHI Announces Second Quarter 2026 Results
• Positive Sentiment: The healthcare REIT declared a quarterly dividend of $0.92 per share, equivalent to $3.68 annually and a reported yield of approximately 5%. The dividend is payable November 6 to shareholders of record September 30. This supports NHI’s income-oriented investment appeal.
• Neutral Sentiment: NHI issued an investor update and supplemental second-quarter portfolio information, giving investors additional detail on its healthcare real estate portfolio and operating performance. NHI Issues Investor Update
• Negative Sentiment: Second-quarter FFO, a key REIT profitability measure, was $1.19 per share, below the $1.26 consensus estimate and down from $1.22 a year earlier. The miss is likely weighing more heavily on investors than the GAAP EPS beat. National Health Investors Q2 FFO Lag Estimates
• Negative Sentiment: Management’s updated FY 2026 EPS guidance of $4.74–$4.79 is below the approximately $4.87 analyst consensus, signaling weaker-than-expected earnings expectations for the year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Truist Financial dropped their price target on shares of National Health Investors from $89.00 to $81.00 and set a "buy" rating for the company in a research note on Friday, June 12th. Cantor Fitzgerald reiterated an "overweight" rating and set a $94.00 target price on shares of National Health Investors in a research note on Wednesday, April 22nd. Weiss Ratings downgraded shares of National Health Investors from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, June 12th. Zacks Research cut shares of National Health Investors from a "hold" rating to a "strong sell" rating in a research note on Thursday, June 25th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of National Health Investors from $85.00 to $80.00 and set a "hold" rating on the stock in a research note on Thursday, June 25th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, National Health Investors presently has an average rating of "Moderate Buy" and a consensus price target of $83.86.

National Health Investors Price Performance

The stock has a market cap of $3.40 billion, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 3.38 and a beta of 0.51. The company has a debt-to-equity ratio of 0.83, a quick ratio of 8.20 and a current ratio of 8.20. The business's fifty day simple moving average is $75.18 and its 200 day simple moving average is $79.56.

National Health Investors Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 6th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.92 per share. This represents a $3.68 dividend on an annualized basis and a yield of 5.2%. The ex-dividend date of this dividend is Wednesday, September 30th. National Health Investors's dividend payout ratio (DPR) is currently 118.71%.

Insider Transactions at National Health Investors

In related news, CEO D. Eric Mendelsohn acquired 1,500 shares of National Health Investors stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $68.84 per share, with a total value of $103,260.00. Following the completion of the acquisition, the chief executive officer directly owned 133,316 shares of the company's stock, valued at $9,177,473.44. This trade represents a 1.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert A. Mccabe, Jr. bought 890 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $71.65 per share, for a total transaction of $63,768.50. Following the acquisition, the director owned 44,159 shares of the company's stock, valued at $3,163,992.35. This represents a 2.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.70% of the company's stock.

Institutional Investors Weigh In On National Health Investors

Large investors have recently modified their holdings of the stock. Renaissance Group LLC boosted its stake in National Health Investors by 3.8% in the 4th quarter. Renaissance Group LLC now owns 3,206 shares of the real estate investment trust's stock worth $245,000 after purchasing an additional 117 shares during the period. Captrust Financial Advisors grew its position in shares of National Health Investors by 1.7% in the fourth quarter. Captrust Financial Advisors now owns 8,907 shares of the real estate investment trust's stock valued at $680,000 after purchasing an additional 146 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in National Health Investors by 34.3% during the first quarter. EverSource Wealth Advisors LLC now owns 626 shares of the real estate investment trust's stock valued at $51,000 after acquiring an additional 160 shares during the period. Assetmark Inc. lifted its position in National Health Investors by 13.5% in the first quarter. Assetmark Inc. now owns 1,356 shares of the real estate investment trust's stock worth $110,000 after purchasing an additional 161 shares during the period. Finally, Inspire Investing LLC boosted its position in shares of National Health Investors by 3.2% during the 1st quarter. Inspire Investing LLC now owns 6,310 shares of the real estate investment trust's stock valued at $510,000 after acquiring an additional 198 shares in the last quarter. 62.51% of the stock is owned by institutional investors.

About National Health Investors

National Health Investors, Inc NYSE: NHI is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company's portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source